(S,E)-3-(3-(4-chlorophenyl)acryloyl)-4-phenyloxazolidin-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (S,E)-3-(3-(4-chlorophenyl)acryloyl)-4-phenyloxazolidin-2-one
• 英文别名: (4S)-3-[(E)-3-(4-chlorophenyl)prop-2-enoyl]-4-phenyl-1,3-oxazolidin-2-one
• 化学式: C₁₈H₁₄ClNO₃
• 分子量: 327.767
• InChiKey: PBMZDPABJDVEOD-YCABEKBOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S,E)-3-(3-(4-chlorophenyl)acryloyl)-4-phenyloxazolidin-2-one 以82.5的产率得到
  参考文献：
  名称：

  METHOD FOR PREPARING CHIRAL BACLOFEN

  摘要：

  本发明提供了一种通过手性迈克尔加成制备手性巴氯芬的新方法，其产量更高，e.e. 值更高，成本更低。

  公开号：

  US20120029230A1
• 作为产物：
  描述：

  对氯肉桂酸 在 N,N-二甲基甲酰胺 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 23.5h， 生成 (S,E)-3-(3-(4-chlorophenyl)acryloyl)-4-phenyloxazolidin-2-one
  参考文献：
  名称：

  METHOD FOR PREPARING CHIRAL BACLOFEN

  摘要：

  本发明提供了一种通过手性Michael加成制备手性巴氯芬的新方法，其产率更高，e.e.值更高，成本更低。

  公开号：

  US20120029230A1

文献信息

• [EN] PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2015013835A1

  公开（公告）日：2015-02-05

  The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

  本发明涉及哌嗪衍生物，包括含有这些衍生物的药物组合物，以及它们在抑制HIV蛋白酶、抑制HIV复制、预防HIV感染、治疗HIV感染以及预防、治疗和延缓艾滋病发病或进展中的用途。
• PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20160159752A1

  公开（公告）日：2016-06-09

  The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

  本发明涉及哌嗪衍生物，包括药物组合物和它们在抑制HIV蛋白酶、抑制HIV复制、预防HIV感染、治疗HIV感染、预防、治疗和延缓艾滋病的发作或进展中的应用。
• Piperazine derivatives as HIV protease inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10138255B2

  公开（公告）日：2018-11-27

  The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

  本发明涉及由其组成的式 I 化合物药物组合物，及其在抑制 HIV 蛋白酶、抑制 HIV 复制、预防 HIV 感染、治疗 HIV 感染以及预防、治疗和延缓 AIDS 的发生或发展中的用途。
• Chakraborty; Ghosh, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2001, vol. 40, # 10, p. 895 - 897
  作者：Chakraborty、Ghosh

  DOI：——

  日期：——
• Ionic Liquid Media Resulted in the First Asymmetric Aminohalogenation Reaction of Alkenes
  作者：Xin Xu、S. R. S. Saibabu Kotti、Junying Liu、John F. Cannon、Allan D. Headley、Guigen Li

  DOI：10.1021/ol048045i

  日期：2004.12.1

  [Graphics]The first asymmetric aminohalogenation of functionalized alkenes has been established. The ionic liquid [bmim][BF4] was found to be the only effective media for success as normal organic solvents failed to give any product for this reaction. The reaction is also very convenient to perform by simply mixing the three reactants, cinnamates, N,N-dichloro-p-toluenesulfonamide, and catalyst, together with 4 A molecular sieves at room temperature in [bmim][BF4] in any convenient vial of appropriate size without special protection from inert gases. Good chemical yields (60-72%) and diastereoselectivities (up to 75% de) have been obtained with a good scope of substrates. The resulting individual diastereomers have been cleanly separated via column chromatography. The absolute stereochemistry of the reaction was unambiguously determined by X-ray structural analysis.